Excessive levels of nitric oxide in rat model of Parkinson's disease induced by rotenone

Xiong,Zhong‑Kui; Lang,Juan; Xu,Gang; Li,Hai‑Yu; Zhang,Yun; Wang,Lei; Su,Yao; Sun,Ai‑Jing

doi:10.3892/etm.2014.2099

Excessive levels of nitric oxide in rat model of Parkinson's disease induced by rotenone

Authors:
- Zhong‑Kui Xiong
- Juan Lang
- Gang Xu
- Hai‑Yu Li
- Yun Zhang
- Lei Wang
- Yao Su
- Ai‑Jing Sun
View Affiliations

Affiliations: Department of Radiotherapy, Shaoxing Second Hospital, Shaoxing, Zhejiang 312000, P.R. China, Medical Research Center, Shaoxing People's Hospital, Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China, Department of Radiotherapy, Jiangsu University Affiliated People's Hospital, Zhenjiang, Jiangsu 212002, P.R. China, Department of Laboratory Medicine, Shaoxing University School of Medicine, Shaoxing, Zhejiang 312099, P.R. China, Department of Basic Medicine, Shaoxing University School of Medicine, Shaoxing, Zhejiang 312099, P.R. China, Department of Clinical Medicine, Shaoxing University School of Medicine, Shaoxing, Zhejiang 312099, P.R. China, Department of Pathology, Shaoxing People's Hospital, Zhejiang University, Shaoxing, Zhejiang, Shaoxing, Zhejiang 312000, P.R. China
Published online on: December 2, 2014 https://doi.org/10.3892/etm.2014.2099
Pages: 553-558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systemic rotenone models of Parkinson's disease (PD) are highly reproducible and may provide evidence on the pathogenesis of PD. In the present study, male Sprague‑Dawley rats (1‑year‑old) were subcutaneously administered with rotenone (1.5 mg/kg/day) for six days and observed for the following three weeks. Compared with the control rats, a significant decrease was observed in the body weight and a marked increase was observed in the areas under the behavioral scoring curves in the rotenone‑treated rats. Immunohistochemical staining revealed that the abundance of nigral tyrosine hydroxylase (TH)‑positive neurons was markedly reduced following rotenone treatment. ELISA and neurochemical assays demonstrated a significant increase in the levels of nitric oxide (NO) and NO synthase, whereas a marked decrease was observed in the thiol levels in the brains of the rotenone‑treated rats. Thus, subacute rotenone treatment was found to induce behavioral deficits and the loss of nigral TH‑positive neurons which may be associated with the excessive levels of NO in the rat brains.

View Figures

View References

1	Gao HM and Hong JS: Gene-environment interactions: key to unraveling the mystery of Parkinson’s disease. Prog Neurobiol. 94:1–19. 2011. View Article : Google Scholar : PubMed/NCBI
2	Venkateshappa C, Harish G, Mythri RB, et al: Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem Res. 37:358–369. 2012. View Article : Google Scholar
3	Fearnley JM and Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 114:2283–2301. 1991. View Article : Google Scholar
4	Marsden CD: Basal ganglia disease. Lancet. 2:1141–1147. 1982. View Article : Google Scholar : PubMed/NCBI
5	Collier TJ, Kanaan NM and Kordower JH: Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primate. Nat Rev Neurosci. 12:359–366. 2011. View Article : Google Scholar : PubMed/NCBI
6	Olanow CW, Stern MB and Sethi K: The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 72(21 Suppl 4): S1–S136. 2009. View Article : Google Scholar : PubMed/NCBI
7	Coppedè F: Genetics and epigenetics of Parkinson’s disease. Scientific World Journal. 2012:4898302012. View Article : Google Scholar
8	Jung J, Na C and Huh Y: Alterations in nitric oxide synthase in the aged CNS. Oxid Med Cell Longev. 2012:7189762012. View Article : Google Scholar : PubMed/NCBI
9	Hwang SJ and Huh Y: Age-related changes in nitric oxide synthase in the lateral geniculate nucleus of rats. J Mol Histol. 41:129–135. 2010. View Article : Google Scholar : PubMed/NCBI
10	Gupta N, Jing Y, Collie ND, Zhang H and Liu P: Ageing alters behavioural function and brain arginine metabolism in male Sprague-Dawley rats. Neuroscience. 226:178–196. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bustamante J, Czerniczyniec A, Cymeryng C and Lores-Arnaiz S: Age related changes from youth to adulthood in rat brain cortex: nitric oxide synthase and mitochondrial respiratory function. Neurochem Res. 33:1216–1223. 2008. View Article : Google Scholar : PubMed/NCBI
12	Hancock DB, Martin ER, Vance JM and Scott WK: Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease. Neurogenetics. 9:249–262. 2008. View Article : Google Scholar : PubMed/NCBI
13	Aquilano K, Baldelli S, Rotilio G and Ciriolo MR: Role of nitric oxide synthases in Parkinson’s disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res. 33:2416–2426. 2008. View Article : Google Scholar : PubMed/NCBI
14	Singh S, Das T, Ravindran A, et al: Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson’s disease. Redox Rep. 10:103–109. 2005. View Article : Google Scholar
15	Tsuboi Y: Environmental-genetic interactions in the pathogenesis of Parkinson’s disease. Exp Neurobiol. 21:123–128. 2012. View Article : Google Scholar : PubMed/NCBI
16	van der Mark M, Vermeulen R, Nijssen PC, Mulleners WM, Sas AM, et al: Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands. Occup Environ Med. 71:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
17	Dhillon AS, Tarbutton GL, Levin JL, et al: Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromedicine. 13:37–48. 2008. View Article : Google Scholar
18	He Y, Imam SZ, Dong Z, et al: Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 86:1338–1345. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bashkatova V, Alam M, Vanin A and Schmidt WJ: Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp Neurol. 186:235–241. 2004. View Article : Google Scholar : PubMed/NCBI
20	Cannon JR, Tapias V, Na HM, et al: A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 34:279–290. 2009. View Article : Google Scholar : PubMed/NCBI
21	Chen X, Zhao Z, Zhao Z and Mu Y: Correlation study between behavioral alteration and nigral pathological injury in rotenone-reduced rats of Parkinson’s disease. Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi. 34:232–234. 2008.
22	Li J, Hou Y, Zhang S, et al: Excess iron undermined bone load-bearing capacity through tumor necrosis factor-α-dependent osteoclastic activation in mice. Biomed Rep. 1:85–88. 2013.PubMed/NCBI
23	Robyt JF, Ackerman RJ and Chittenden CG: Reaction of protein disulfide groups with Ellman’s reagent: a case study of the number of sulfhydryl and disulfide groups in Aspergillus oryzae -amylase, papain, and lysozyme. Arch Biochem Biophys. 147:262–269. 1971. View Article : Google Scholar : PubMed/NCBI
24	Drolet RE, Cannon JR, Montero L and Greenamyre JT: Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiol Dis. 36:96–102. 2009. View Article : Google Scholar : PubMed/NCBI
25	Olanow CW and Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144. 1999. View Article : Google Scholar
26	Beal MF: Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann Neurol. 44:S110–S114. 1998. View Article : Google Scholar : PubMed/NCBI
27	Jenner P and Olanow CW: Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 47:S161–S170. 1996. View Article : Google Scholar : PubMed/NCBI
28	Taetzsch T and Block ML: Pesticides, microglial NOX2, and Parkinson’s disease. J Biochem Mol Toxicol. 27:137–149. 2013. View Article : Google Scholar : PubMed/NCBI
29	Wu YN and Johnson SW: Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons. Neuroscience. 195:138–144. 2011. View Article : Google Scholar : PubMed/NCBI
30	Joniec I, Ciesielska A, Kurkowska-Jastrzebska I, et al: Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 1261:7–19. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bai Q, He J, Qiu J, et al: Rotenone induces KATP channel opening in PC12 cells in association with the expression of tyrosine hydroxylase. Oncol Rep. 28:1376–1384. 2012.PubMed/NCBI
32	Richter F, Hamann M and Richter A: Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res. 85:681–691. 2007. View Article : Google Scholar
33	Coulom H and Birman S: Chronic exposure to rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci. 24:10993–10998. 2004. View Article : Google Scholar : PubMed/NCBI
34	Inden M, Kitamura Y, Takeuchi H, et al: Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem. 101:1491–1504. 2007. View Article : Google Scholar : PubMed/NCBI
35	Pan-Montojo F, Schwarz M, Winkler C, et al: Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2:8982012. View Article : Google Scholar : PubMed/NCBI
36	Ebadi M, Sharma SK, et al: Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role of metallothioneins. Methods Enzymol. 396:276–298. 2005. View Article : Google Scholar
37	Levecque C, Elbaz A, Clavel J, et al: Association between Parkinson’s disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. Hum Mol Genet. 12:79–86. 2003. View Article : Google Scholar
38	Huerta C, Sanchez-Ferrero E, Coto E, et al: No association between Parkinson’s disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neurosci Lett. 413:202–205. 2007. View Article : Google Scholar
39	Tuncel D, Inanc Tolun F and Toru I: Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson’s disease. Mediators Inflamm. 2009:1324642009. View Article : Google Scholar
40	Huskic J, Paperniku A, Husic A, Alendar F and Mulabegovic N: Significantly reduced salivary nitric oxide synthesis in patients with Parkinson’s disease. Bosn J Basic Med Sci. 5:86–89. 2005.
41	Chung KK, Dawson VL and Dawson TM: S-nitrosylation in Parkinson’s disease and related neurodegenerative disorders. Methods Enzymol. 396:139–150. 2005. View Article : Google Scholar
42	Chung KK, Thomas B, Li X, et al: S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science. 304:1328–1331. 2004. View Article : Google Scholar : PubMed/NCBI
43	Uehara T, Nakamura T, Yao D, et al: S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 441:513–517. 2006. View Article : Google Scholar : PubMed/NCBI
44	Borutaite V and Brown GC: S-nitrosothiol inhibition of mitochondrial complex I causes a reversible increase in mitochondrial hydrogen peroxide production. Biochim Biophys Acta. 1757:562–566. 2006. View Article : Google Scholar : PubMed/NCBI
45	Fang J, Nakamura T, Cho DH, Gu Z and Lipton SA: S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson’s disease. Proc Natl Acad Sci USA. 104:18742–18747. 2007. View Article : Google Scholar
46	Schildknecht S, Gerding HR, Karreman C, et al: Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem. 125:491–511. 2013. View Article : Google Scholar : PubMed/NCBI
47	Nunes C, Barbosa RM, Almeida L and Laranjinha J: Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis. Mol Cell Neurosci. 48:94–103. 2011. View Article : Google Scholar : PubMed/NCBI
48	Chinta SJ and Andersen JK: Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson’s disease. Free Radic Biol Med. 41:1442–1448. 2006. View Article : Google Scholar : PubMed/NCBI
49	Di Monte DA, Chan P and Sandy MS: Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Ann Neurol. 32(Suppl): S111–S115. 1992. View Article : Google Scholar